Reuters -- ARYx Therapeutics Inc said U.S. health regulators confirmed that the current development pathway for its experimental anticoagulant agent remains acceptable to seek regulatory approval.
Reuters -- ARYx Therapeutics Inc said U.S. health regulators confirmed that the current development pathway for its experimental anticoagulant agent remains acceptable to seek regulatory approval.
